Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Zymeworks closes $61.5mm mezzanine round

Executive Summary

Zymeworks Inc. (bispecific antibodies and conjugates for cancer, autoimmune, and inflammatory diseases) raised $61.5mm through what the company is calling a Series A mezzanine round. New investors BDC Capital and Lumira Capital co-led, and were joined by existing backers Eli Lilly, Celgene, CTI Life Sciences Fund, and the Fonds de solidarité FTQ. New investors Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital, and Merlin Nexus also participated.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies